In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK is also working on expanding the label of marketed products like Nucala, Zejula and Jemperli into additional indications.

GSK has continued to beat my expectations as ... The company's oncology portfolio, consisting of Zejula, Blenrep, Jemperli, and Ojjaara/Omjjara, reported total sales of $450 million in the second ...

GSK has a strong portfolio of marketed drugs for oncology indications, including Jemperli (dostarlimab), Zejula (niraparib) and Ojjaara, which are approved for various cancer indications.

GSK reported adjusted earnings of 72 cents per ... registered impressive growth on the back of rising Jemperli and Zejula sales and the newly-launched Ojjaara. Sales in the United States rose ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...

Wolff Olins has created the new brand identity for global healthcare company GSK (formerly GlaxoSmithKline), aiming to better express its focus on innovation. The agency was brought on board around 18 ...

GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...